Page last updated: 2024-08-23

pravastatin and Obesity

pravastatin has been researched along with Obesity in 22 studies

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (13.64)18.2507
2000's10 (45.45)29.6817
2010's9 (40.91)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ávila-González, AE; García-Cobian, TA; García-Iglesias, T; Pérez-Guerrero, EE; Raffoul-Orozco, AK; Rodríguez-Razón, CM; Rubio-Arellano, ED1
Beck, B; Donner, D; du Toit, EF; Headrick, JP; Oi, M; Peart, J; Wendt, L1
Hur, J; Kang, JY; Kim, YK; Lee, SY; Liang, L; Rhee, CK1
Christopher-Stine, L; Isackson, PJ; Kitzmiller, JP; Luzum, JA; Ma, C; Nguyen, LM; Ochs-Balcom, HM; Peltier, W; Tarnopolsky, M; Vladutiu, GD; Weisman, M; Wortmann, RL1
Barron, FE; Burridge, PW; Churko, JM; Diecke, S; Gold, JD; Gu, M; He, C; Hu, S; Kooreman, NG; Lee, J; Mordwinkin, NM; Ong, SG; Wu, H; Wu, JC1
Cosentino, F; Costantino, S; Paneni, F1
Araki, K; Kakuma, T; Katsuragi, I; Masaki, T; Yoshimatsu, H1
Kushiro, T; Mizuno, K; Nakamura, H; Nakaya, N; Ohashi, Y; Tajima, N; Teramoto, T; Uchiyama, S1
Anazawa, T; Furuya, S; Hirayama, A; Iida, K; Kawamata, H; Kumabe, N; Matsumoto, M; Nagao, K; Takahashi, H; Tani, S; Washio, T1
Acharjee, S; Cannon, CP1
Wilke, RA1
Cobbe, S; Ford, I; Logue, J; Macfarlane, P; Murray, HM; Packard, C; Sattar, N; Shepherd, J; Welsh, P1
Schück, O; Stollová, M; Teplan, V; Vítko, S1
Cobbe, SM; Ford, I; Gaw, A; Haffner, SM; Isles, C; Macfarlane, PW; O'Reilly, DS; Packard, CJ; Sattar, N; Scherbakova, O; Shepherd, J1
Matsui, T; Sato, T; Takeuchi, M; Yamagishi, S1
Hazen, SL; Nicholls, SJ; Nissen, SE; Ntanios, F; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wun, CC1
Magi, L; Morosini, P; Rafaiani, S; Settembri, P; Sforza, P1
Abe, M; Caslake, MJ; Fukuhara, A; Funahashi, T; Kihara, S; Kobayashi, H; Komuro, R; Matsuda, M; McMahon, A; Shepherd, J; Shimomura, I; Takagi, T1
Abe, M; Fukuhara, A; Kobayashi, H; Komuro, R; Matsuda, M; Miyata, Y; Nakayama, Y; Shimomura, I1
Boni, M; De Sio, G; Mazzanti, L; Monteburini, T; Polenta, M; Testa, I1
Barrett e Pesquisadores, AC1
Albarrán, OG; García-Robles, R; Rábano, A; Ruilope, LM; Villa, E1

Reviews

2 review(s) available for pravastatin and Obesity

ArticleYear
Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers.
    Critical pathways in cardiology, 2010, Volume: 9, Issue:3

    Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Obesity; Office Visits; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Risk Assessment; Smoking; United States

2010
High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome.
    The pharmacogenomics journal, 2011, Volume: 11, Issue:3

    Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Databases, Nucleic Acid; Dose-Response Relationship, Drug; Dyslipidemias; Electronic Health Records; Genetic Association Studies; Genetic Markers; Heptanoic Acids; Humans; Obesity; Pravastatin; Pyrroles; Risk Assessment; Simvastatin; Treatment Outcome

2011

Trials

4 trial(s) available for pravastatin and Obesity

ArticleYear
Association of body mass index with coronary plaque regression: 6-month prospective study.
    Journal of atherosclerosis and thrombosis, 2009, Volume: 16, Issue:3

    Topics: Aged; Body Mass Index; Cholesterol; Cholesterol, HDL; Coronary Artery Disease; Female; Humans; Leukocyte Count; Male; Middle Aged; Obesity; Pravastatin; Prospective Studies; Treatment Outcome; Ultrasonography

2009
Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation.
    Heart (British Cardiac Society), 2011, Volume: 97, Issue:7

    Topics: Body Mass Index; Coronary Disease; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Obesity; Poverty; Pravastatin; Risk Factors; Scotland

2011
Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study).
    The American journal of cardiology, 2006, Jun-01, Volume: 97, Issue:11

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Body Mass Index; C-Reactive Protein; Coronary Disease; Coronary Vessels; Disease Progression; Endosonography; Female; Heptanoic Acids; Humans; Inflammation; Lipids; Male; Middle Aged; Obesity; Pravastatin; Pyrroles; Risk Factors

2006
[Pravastatin multicenter clinical trial in patients with hypercholesterolemia and multiple risk factors].
    Arquivos brasileiros de cardiologia, 1997, Volume: 68, Issue:1

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Diabetes Complications; Female; Humans; Hypercholesterolemia; Hypertension; Male; Menopause; Middle Aged; Obesity; Pravastatin; Risk Factors; Sex Factors; Smoking

1997

Other Studies

16 other study(ies) available for pravastatin and Obesity

ArticleYear
Combination effect naringin and pravastatin in lipid profile and glucose in obese rats.
    Life sciences, 2018, Jan-15, Volume: 193

    Topics: Animals; Blood Glucose; Cholesterol, HDL; Drug Therapy, Combination; Flavanones; Glucose; Lipid Metabolism; Lipids; Male; Obesity; Pravastatin; Rats; Rats, Wistar; Triglycerides

2018
Pravastatin improves risk factors but not ischaemic tolerance in obese rats.
    European journal of pharmacology, 2018, May-05, Volume: 826

    Topics: Animals; Blood Glucose; Body Weight; Diet, Carbohydrate Loading; Diet, High-Fat; Disease Models, Animal; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Insulin Resistance; Lipid Peroxidation; Male; Mitochondria; Mitochondrial Dynamics; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Obesity; Pravastatin; Rats; Rats, Wistar; Risk Factors

2018
Effect of the anti-IL-17 antibody on allergic inflammation in an obesity-related asthma model.
    The Korean journal of internal medicine, 2018, Volume: 33, Issue:6

    Topics: Adiponectin; Adipose Tissue; Animals; Anti-Asthmatic Agents; Antibodies; Asthma; Bronchoconstriction; Diet, High-Fat; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-17; Leptin; Lung; Mice, Inbred C57BL; Obesity; Pravastatin; Th17 Cells; Th2 Cells

2018
Clinical features related to statin-associated muscle symptoms.
    Muscle & nerve, 2019, Volume: 59, Issue:5

    Topics: Aged; Atorvastatin; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Logistic Models; Lovastatin; Male; Medical History Taking; Middle Aged; Muscle Weakness; Muscular Diseases; Myalgia; Obesity; Odds Ratio; Pravastatin; Retrospective Studies; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Smoking; White People

2019
Pravastatin reverses obesity-induced dysfunction of induced pluripotent stem cell-derived endothelial cells via a nitric oxide-dependent mechanism.
    European heart journal, 2015, Apr-01, Volume: 36, Issue:13

    Topics: Analysis of Variance; Animals; Apoptosis; Cell Differentiation; Diet, High-Fat; Endothelial Cells; Enzyme Inhibitors; Fibroblasts; Hindlimb; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Induced Pluripotent Stem Cells; Injections, Intramuscular; Ischemia; Mice, Inbred C57BL; Muscle, Skeletal; Muscular Diseases; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Obesity; Oxidative Stress; Pravastatin; Proto-Oncogene Proteins c-akt; Random Allocation; Reperfusion Injury; Signal Transduction

2015
Obesity-induced impairment of pluripotent stem cells: novel insights into vascular repair strategies.
    European heart journal, 2019, 09-07, Volume: 40, Issue:34

    Topics: Cell Differentiation; Endothelial Cells; Humans; Induced Pluripotent Stem Cells; Nitric Oxide; Obesity; Pluripotent Stem Cells; Pravastatin

2019
Effects of pravastatin on obesity, diabetes, and adiponectin in diet-induced obese mice.
    Obesity (Silver Spring, Md.), 2008, Volume: 16, Issue:9

    Topics: Adiponectin; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Eating; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Obesity; Oxygen Consumption; Pravastatin; Random Allocation; Resistin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triglycerides

2008
Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial.
    Journal of the neurological sciences, 2009, Sep-15, Volume: 284, Issue:1-2

    Topics: Adult; Aged; Alcohol Drinking; Cholesterol; Combined Modality Therapy; Comorbidity; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Incidence; Japan; Lipoprotein(a); Male; Middle Aged; Obesity; Pravastatin; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; Sex Factors; Smoking; Stroke

2009
Obesity and hyperhomocysteinaemia after kidney transplantation.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2003, Volume: 18 Suppl 5

    Topics: Adult; Aged; Cohort Studies; Combined Modality Therapy; Diet Therapy; Drug Therapy, Combination; Female; Folic Acid; Follow-Up Studies; Graft Rejection; Graft Survival; Humans; Hyperhomocysteinemia; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Obesity; Postoperative Complications; Pravastatin; Probability; Prospective Studies; Risk Assessment; Treatment Outcome; Vitamin B 6

2003
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.
    Circulation, 2003, Jul-29, Volume: 108, Issue:4

    Topics: Body Mass Index; C-Reactive Protein; Cohort Studies; Comorbidity; Coronary Disease; Diabetes Mellitus; Follow-Up Studies; Humans; Incidence; Male; Metabolic Syndrome; Middle Aged; Multivariate Analysis; Obesity; Pravastatin; Predictive Value of Tests; Risk Assessment; Scotland; Triglycerides

2003
Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
    Medical hypotheses, 2006, Volume: 66, Issue:3

    Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; Male; Metabolic Syndrome; Models, Biological; Models, Theoretical; Obesity; Pravastatin

2006
[Statin therapy: cost-effectiveness and evaluation of evidence as criterium for improving expenditure within the National Health Program].
    Recenti progressi in medicina, 2006, Volume: 97, Issue:5

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Coronary Artery Disease; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Humans; Italy; Middle Aged; National Health Programs; Obesity; Pravastatin; Thyroiditis, Autoimmune

2006
Effect of pravastatin on the development of diabetes and adiponectin production.
    Atherosclerosis, 2008, Volume: 196, Issue:1

    Topics: Adipocytes; Adiponectin; Animals; Diabetes Mellitus; Disease Models, Animal; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Obesity; Pravastatin

2008
Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-beta pathway in macrophages.
    Arteriosclerosis, thrombosis, and vascular biology, 2008, Volume: 28, Issue:5

    Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interferon Regulatory Factor-3; Interferon-beta; Interleukin-6; Macrophages; Male; Mice; Mice, Obese; Myeloid Differentiation Factor 88; Obesity; Pravastatin; Quinolines; Signal Transduction; Toll-Like Receptor 4

2008
[Treatment of hyperlipidemia in obese patients: monotherapy versus bi-therapy].
    Presse medicale (Paris, France : 1983), 1995, Jan-07, Volume: 24, Issue:1

    Topics: Adult; Bezafibrate; Cholesterol; Cholesterol, HDL; Drug Evaluation; Drug Therapy, Combination; Humans; Hyperlipidemias; Male; Middle Aged; Obesity; Pravastatin; Triglycerides

1995
Effects of chronic combined treatment with captopril and pravastatin on the progression of insulin resistance and cardiovascular alterations in an experimental model of obesity in dogs.
    American journal of hypertension, 1998, Volume: 11, Issue:7

    Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Captopril; Cardiovascular Diseases; Cholesterol; Coronary Vessels; Disease Models, Animal; Disease Progression; Dogs; Drug Therapy, Combination; Heart; Insulin; Insulin Resistance; Linear Models; Male; Multivariate Analysis; Myocardium; Obesity; Pravastatin; Triglycerides

1998